Severe Eosinophilic Asthma Not Yet Recruiting Phase 4 Trials for Benralizumab (DB12023)

IndicationStatusPhase
DBCOND0078144 (Severe Eosinophilic Asthma)Not Yet Recruiting4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04159519A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With BenralizumabTreatment
NCT03652376Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic AsthmaBasic Science